Bayforest Capital Ltd Has $517,000 Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Key Points

• Bayforest Capital Ltd significantly increased its stake in Medpace Holdings, Inc. by 469.8%, owning 1,698 shares worth approximately $517,000 after purchasing 1,400 additional shares in Q1.
• Insider trading activity included a sale of 41,801 shares by President Jesse J. Geiger, which indicated a decrease in their holding by 53.38%.
• Analysts have varied ratings for Medpace, with a consensus rating of "Hold" and an average price target of $406.60, reflecting differing outlooks on the stock's future performance.

Bayforest Capital Ltd boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 469.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,698 shares of the company's stock after acquiring an additional 1,400 shares during the period. Bayforest Capital Ltd's holdings in Medpace were worth $517,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in MEDP. Invesco Ltd. lifted its holdings in shares of Medpace by 91.8% during the fourth quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock worth $360,387,000 after buying an additional 519,186 shares in the last quarter. Wasatch Advisors LP raised its stake in Medpace by 3.1% in the 4th quarter. Wasatch Advisors LP now owns 936,842 shares of the company's stock worth $311,247,000 after purchasing an additional 28,161 shares in the last quarter. Mawer Investment Management Ltd. bought a new stake in Medpace in the 1st quarter valued at about $212,131,000. Geode Capital Management LLC grew its position in shares of Medpace by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 656,130 shares of the company's stock worth $218,031,000 after purchasing an additional 28,076 shares in the last quarter. Finally, Bessemer Group Inc. increased its holdings in shares of Medpace by 1.1% during the first quarter. Bessemer Group Inc. now owns 582,269 shares of the company's stock worth $177,411,000 after purchasing an additional 6,225 shares during the period. Institutional investors own 77.98% of the company's stock.

Insider Activity

In other Medpace news, President Jesse J. Geiger sold 41,801 shares of the business's stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $453.11, for a total transaction of $18,940,451.11. Following the completion of the transaction, the president owned 36,503 shares of the company's stock, valued at approximately $16,539,874.33. The trade was a 53.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the company's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the completion of the transaction, the general counsel directly owned 10,343 shares of the company's stock, valued at $4,654,350. This represents a 22.48% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 112,788 shares of company stock valued at $51,018,354. Corporate insiders own 20.30% of the company's stock.

Medpace Trading Up 1.0%

NASDAQ MEDP traded up $4.03 during trading on Monday, hitting $427.12. 100,799 shares of the company's stock were exchanged, compared to its average volume of 461,617. The company has a market cap of $12.00 billion, a PE ratio of 31.81, a P/E/G ratio of 2.66 and a beta of 1.42. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $501.30. The stock's 50 day moving average price is $333.51 and its two-hundred day moving average price is $323.96.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10. The firm had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%. The business's quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.75 earnings per share. Analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft boosted their price target on Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a research note on Wednesday, July 23rd. Truist Financial lifted their price objective on Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. Mizuho increased their target price on Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Cowen cut Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. Finally, UBS Group downgraded Medpace from a "neutral" rating to a "sell" rating and boosted their price target for the company from $300.00 to $305.00 in a research note on Tuesday, July 29th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, Medpace presently has an average rating of "Hold" and an average target price of $406.60.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.